Spots Global Cancer Trial Database for Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer
Official Title: A Phase 2 Multicenter Study Evaluating the Efficacy and Safety of IPI-504 in Combination With Trastuzumab in Patients With Pretreated, Locally Advanced or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
Study ID: NCT00817362
Study Description
Brief Summary: The purpose of this study is to see if IPI-504 in combination with trastuzamab is an effective treatment in HER2 positive metastatic breast cancer
Detailed Description: Recent clinical data has demonstrated that even in heavily pretreated patients with trastuzumab-refractory HER-2 positive breast cancer, targeting HER2 is efficacious. IPI-504 is an HSP90 inhibitor and is chemically related to 17-AAG and it has been studied in a clinical trial in combination with trastuzamab and a response rate of 26% (7/27) was demonstrated in patients with pretreated, HER2-positive breast cancer. These data provide a strong scientific rationale for clinical testing of IPI-504 plus trastuzumab in patients with pretreated, locally advanced or metastatic HER2-positive breast cancer
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Comprehensive Cancer Center at Desert Regional Medical Center, Palm Springs, California, United States
Boca Raton Comphrensive Cancer Care, Boca Raton, Florida, United States
Florida Cancer Research Institute, Davie, Florida, United States
Peachtree Hematology-Oncology Consultants, P.C., Atlanta, Georgia, United States
Medical College of Georgia Cancer Center, Augusta, Georgia, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Weill Cornell Breast Center, New York, New York, United States
West Cancer Clinic, Memphis, Tennessee, United States
US Oncology, Dallas, Texas, United States
Vall d'Hebron Institute of Oncology (V.H.I.O.), Barcelona, , Spain
Contact Details
Name: Pedro Santabarbara, MD
Affiliation: Infinity Pharmaceuticals, Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
